This article provides an update on the classification, definitions, diagnostic criteria, and treatments of diabetic neuropathies, including peripheral neuropathy (DPN), autonomic neuropathy, painful DPN, and structural alterations in DPN. It outlines the distinction between typical DPN (DSPN) and atypical DPN, emphasizing the importance of objective measures such as nerve conduction studies (NC) in diagnosis. The severity of DSPN is graded based on NC abnormalities, with grades ranging from 0 to 2b. The article also discusses the minimal criteria for diagnosing DSPN, including possible, probable, confirmed, and subclinical cases. For atypical DPN, the focus is on the need for further research and characterization. Painful DPN is defined as pain arising from abnormalities in the peripheral somatosensory system in diabetes. It is associated with a range of symptoms, including prickling, burning, and sharp pain, often in the feet and legs. The severity of pain can be assessed using validated scales such as the visual analog scale and the numerical rating scale. Treatment options include tricyclic antidepressants, anticonvulsants, and opioids, with a focus on symptom management rather than addressing the underlying cause. Diabetic autonomic neuropathy (DAN) affects the autonomic nervous system and can impact cardiovascular, gastrointestinal, and urogenital systems. Diagnosis involves cardiovascular reflex tests, which are considered the gold standard for autonomic testing. The severity of DAN is assessed using various tests, including heart rate variability and blood pressure responses. DAN is associated with increased cardiovascular risk and mortality. Gastrointestinal autonomic neuropathy can lead to symptoms such as delayed esophageal transit, gastroparesis, and altered bowel function. Diagnosis involves assessing GI symptoms, quality of life, and motility. Bladder dysfunction in diabetes can result from detrusor muscle dysfunction, neuronal issues, and urothelial dysfunction. Diagnosis includes urodynamic testing and validated questionnaires. Erectile dysfunction is a common complication of diabetes, often linked to neuropathy, vascular issues, and hormonal changes. Diagnosis involves comprehensive patient history and validated questionnaires. Bladder dysfunction is assessed using urodynamic tests and validated questionnaires. Sudomotor dysfunction, characterized by reduced sweat production, is assessed using quantitative sudomotor axon reflex test (QSART) and other methods. Emerging markers of DPN, such as small fiber neuropathy (SFN), are discussed, with emphasis on the role of skin biopsy and corneal confocal microscopy in detecting early damage. The article concludes that diabetic neuropathy is a common long-term complication of diabetes, affecting approximately 50% of all diabetic individuals. It emphasizes the need for updated diagnostic criteria and ongoing research to improve the management of diabetic neuropathies.This article provides an update on the classification, definitions, diagnostic criteria, and treatments of diabetic neuropathies, including peripheral neuropathy (DPN), autonomic neuropathy, painful DPN, and structural alterations in DPN. It outlines the distinction between typical DPN (DSPN) and atypical DPN, emphasizing the importance of objective measures such as nerve conduction studies (NC) in diagnosis. The severity of DSPN is graded based on NC abnormalities, with grades ranging from 0 to 2b. The article also discusses the minimal criteria for diagnosing DSPN, including possible, probable, confirmed, and subclinical cases. For atypical DPN, the focus is on the need for further research and characterization. Painful DPN is defined as pain arising from abnormalities in the peripheral somatosensory system in diabetes. It is associated with a range of symptoms, including prickling, burning, and sharp pain, often in the feet and legs. The severity of pain can be assessed using validated scales such as the visual analog scale and the numerical rating scale. Treatment options include tricyclic antidepressants, anticonvulsants, and opioids, with a focus on symptom management rather than addressing the underlying cause. Diabetic autonomic neuropathy (DAN) affects the autonomic nervous system and can impact cardiovascular, gastrointestinal, and urogenital systems. Diagnosis involves cardiovascular reflex tests, which are considered the gold standard for autonomic testing. The severity of DAN is assessed using various tests, including heart rate variability and blood pressure responses. DAN is associated with increased cardiovascular risk and mortality. Gastrointestinal autonomic neuropathy can lead to symptoms such as delayed esophageal transit, gastroparesis, and altered bowel function. Diagnosis involves assessing GI symptoms, quality of life, and motility. Bladder dysfunction in diabetes can result from detrusor muscle dysfunction, neuronal issues, and urothelial dysfunction. Diagnosis includes urodynamic testing and validated questionnaires. Erectile dysfunction is a common complication of diabetes, often linked to neuropathy, vascular issues, and hormonal changes. Diagnosis involves comprehensive patient history and validated questionnaires. Bladder dysfunction is assessed using urodynamic tests and validated questionnaires. Sudomotor dysfunction, characterized by reduced sweat production, is assessed using quantitative sudomotor axon reflex test (QSART) and other methods. Emerging markers of DPN, such as small fiber neuropathy (SFN), are discussed, with emphasis on the role of skin biopsy and corneal confocal microscopy in detecting early damage. The article concludes that diabetic neuropathy is a common long-term complication of diabetes, affecting approximately 50% of all diabetic individuals. It emphasizes the need for updated diagnostic criteria and ongoing research to improve the management of diabetic neuropathies.